Tag Archives: Study

Nepal: New Study by ICTJ Finds Conflict Victims Continue to Have Acute Needs; Calls for Comprehensive Reparations


KATHMANDU (PRWEB) September 17, 2014

A new study by the International Center for Transitional Justice finds that victims of human rights violations committed during Nepal’s 10-year armed conflict continue to experience hardship – and calls on the government to implement a comprehensive reparations program to respond to their acute and long-term needs.

In 2008, the government of Nepal introduced an Interim Relief Program (IRP) to provide assistance to individuals who had suffered human rights abuses during the internal armed conflict. Since then, tens of thousands of people have received benefits in the form of cash payments, scholarships, reimbursement of medical costs, compensation for loss of or damage to property, and skills training.

However, according to the ICTJ study, titled “‘To Walk Freely with a Wide Heart’: A Study of the Needs and Aspirations for Reparative Justice of Victims of Conflict-Related Abuses in Nepal,” the state has not yet addressed the full harms suffered by conflict victims or significantly contributed to repairing them.

More than 400 victims of human rights abuses by state and Maoist forces were interviewed for the study, which was jointly undertaken by the Center for Research on Environment Health and Population Activities (CREHPA), in 10 Nepali districts. Victims participated in group discussions that probed their short- and long-term needs and expectations for reparations.

“Our goal was to hear directly from survivors and the families of victims to give them the chance to identify needs resulting from, or exacerbated by, violations they experienced, and the forms of reparations and transitional justice measures they want prioritized,” explained Ruben Carranza, director of ICTJ’s Reparative Justice Program. “We spoke with victims who had received benefits through the IRP as well as those who had been excluded.”

The study revealed that in many cases victims were already disadvantaged before the conflict, due to poverty, caste, or other forms of economic marginalization or social discrimination. Violations had left some in situations of extreme poverty. Women in particular reported deteriorating physical and mental health while continuing to carry enormous economic burdens, often resulting from the loss of a husband or family breadwinner.

A significant number of participants reported spending what little money they had on medical bills, legal costs, and the search for disappeared loved ones. Ranked consistently at the top of the list of immediate needs were financial support, employment, free education, free medical care, and subsistence needs (“food, shelter, and clothing”).

Torture survivors spoke of their worsening physical and psychological condition and their anger and frustration at having received no care.

As a torture survivor in Kapilvastu reported: “I was tortured badly by the security forces. They accused me of sheltering Maoists. I had severe injuries and had to spend over four lakh [USD $ 4,000] on treatment . . . I’ve spent all of my savings. Now I’m worried about my children. How will I feed and educate them?”

Looking beyond immediate needs, the study also revealed a more holistic understanding of “justice” among respondents. Victims shared their broad aspirations for measures that would address the moral and nonmaterial dimension of harms, including the punishment of perpetrators, truth seeking, searching for the disappeared, and long-term security and protection.

The report stresses that the government should not wait for a Truth and Reconciliation Commission to complete its work before carrying out a comprehensive reparation program, as this could take many years. Any additional delays would further compromise victims’ rights to restitution.

“The findings are a stark reminder of the extent of suffering endured by conflict victims, who continue to wait for a full reparations program to receive the care and compensation they need and have a legal right to receive,” said Jan Borgen, ICTJ’s Head of Office in Nepal. “Much more needs to be done by the government to address these harms.”

The full report can be downloaded in English and Nepali.







Baptist Jacksonville First to Enroll Patients in Global Study to Treat Brain Aneurysms

Jacksonville, Fla. (PRWEB) September 15, 2014

Baptist Medical Center Jacksonville is the first hospital in the world to enroll a patient in an international study that is assessing a new way to treat brain aneurysms.

Baptist Jacksonville is one of 20 sites globally that will be studying a device that has traditionally been used for larger aneurysms in the brain. A cerebral aneurysm is an area where a blood vessel in the brain weakens, resulting in a bulging or ballooning of part of the vessel wall.

The study hopes to expand the use of the Pipeline™ Embolization Device, a braided cylindrical mesh also called a flow diverter, which slows the flow of blood into the aneurysm and allows the diseased vessel to heal. The study will evaluate the device in the treatment of small and medium unruptured brain aneurysms. The device is inserted through a microcatheter into an artery in the groin and threaded through the body to the brain.

Baptist Jacksonville is playing a leadership role in the PREMIER Prospective study sponsored by Covidien and providing advanced training for many visiting physicians on the device using elaborate simulators.

“Being the first to enroll a patient in this trial demonstrates the commitment of Baptist and Lyerly Neurosurgery to clinical research and expanding options for brain aneurysm treatment in the region,” said Ricardo Hanel, MD, PhD, director of the Stroke & Cerebrovascular Center at Baptist Jacksonville and neurovascular surgeon with Lyerly Neurosurgery.

Baptist Jacksonville treated the first patient at the end of July. Baptist is the lead enrolling center with three patients treated in Jacksonville, including Dana Bean, 52, of Fernandina Beach. She had the procedure after having her small aneurysm monitored the past six years.

“I was sitting on a time bomb of not knowing. That is the scary thing about it,” Bean said, whose mother and grandfather died from an aneurysm. “The question of when and if it was going to happen was always there. It’s one of those things where you wake up in the middle of the night and think ‘what if’ and you start thinking about the people you love.”

The study looks at using the pipeline technique for aneurysms 12 mm and smaller and in various locations of the brain.

“This study will show the benefit of this breakthrough technology for smaller aneurysms and that patients can do well with these treatments,” Dr. Hanel said. “This will make it widely available for use by more patients.”

The pipeline procedure is more efficient, Dr. Hanel added, compared to other techniques such as coiling because, once the aneurysm is closed off, the possibility of the aneurysm reoccurring with the pipeline is close to zero.

The Baptist Stroke & Cerebrovascular Center hopes to enroll 20 to 25 people during the next six months, ages 22 to 80, and will continue to enroll patients for two years. Patients will be followed for a five-year period.

“Baptist Jacksonville is at the forefront in the assessment of newer technologies to improve the care of patients with brain aneurysms and strokes,” said neurovascular surgeon Eric Sauvageau, MD, who directs the Stroke & Cerebrovascular Center with Dr. Hanel.

For Bean, who is married and a sales manager for a dairy, she said, “There is a huge weight lifted off.” She’ll be monitored during the coming months and in six months, the aneurysm is expected to be gone.

“It’s an amazing thing they are doing. I think of how many people this could save,” Bean said.

Every year, an estimated 40,000 people in the United States experience a ruptured cerebral aneurysm and about 4 percent of the population may be living with an unruptured aneurysm.

###

About Baptist Health

Baptist Health is a faith-based, mission-driven system in Northeast Florida comprised of Baptist Medical Center Jacksonville; Baptist Medical Center Beaches; Baptist Medical Center Nassau; Baptist Medical Center South; Baptist Clay Medical Campus and Wolfson Children’s Hospital – the region’s only children’s hospital. All Baptist Health hospitals, along with Baptist Home Health Care, have achieved Magnet™ status for excellence in patient care. Baptist Health includes the area’s only dedicated heart hospital; a cancer center; orthopedic institute; women’s services; neurological institute, including comprehensive neurosurgical services, a comprehensive stroke center and two primary stroke centers; a Bariatric Center of Excellence; a full range of psychology and psychiatry services; outpatient facilities; urgent care services; and primary and specialty care physicians’ offices throughout Northeast Florida. For more details, visit baptistjax.com. For information on Wolfson Children’s Hospital, visit http://www.wolfsonchildrens.org.







Baptist Jacksonville First to Enroll Patients in Global Study to Treat Brain Aneurysms

Jacksonville, Fla. (PRWEB) September 15, 2014

Baptist Medical Center Jacksonville is the first hospital in the world to enroll a patient in an international study that is assessing a new way to treat brain aneurysms.

Baptist Jacksonville is one of 20 sites globally that will be studying a device that has traditionally been used for larger aneurysms in the brain. A cerebral aneurysm is an area where a blood vessel in the brain weakens, resulting in a bulging or ballooning of part of the vessel wall.

The study hopes to expand the use of the Pipeline™ Embolization Device, a braided cylindrical mesh also called a flow diverter, which slows the flow of blood into the aneurysm and allows the diseased vessel to heal. The study will evaluate the device in the treatment of small and medium unruptured brain aneurysms. The device is inserted through a microcatheter into an artery in the groin and threaded through the body to the brain.

Baptist Jacksonville is playing a leadership role in the PREMIER Prospective study sponsored by Covidien and providing advanced training for many visiting physicians on the device using elaborate simulators.

“Being the first to enroll a patient in this trial demonstrates the commitment of Baptist and Lyerly Neurosurgery to clinical research and expanding options for brain aneurysm treatment in the region,” said Ricardo Hanel, MD, PhD, director of the Stroke & Cerebrovascular Center at Baptist Jacksonville and neurovascular surgeon with Lyerly Neurosurgery.

Baptist Jacksonville treated the first patient at the end of July. Baptist is the lead enrolling center with three patients treated in Jacksonville, including Dana Bean, 52, of Fernandina Beach. She had the procedure after having her small aneurysm monitored the past six years.

“I was sitting on a time bomb of not knowing. That is the scary thing about it,” Bean said, whose mother and grandfather died from an aneurysm. “The question of when and if it was going to happen was always there. It’s one of those things where you wake up in the middle of the night and think ‘what if’ and you start thinking about the people you love.”

The study looks at using the pipeline technique for aneurysms 12 mm and smaller and in various locations of the brain.

“This study will show the benefit of this breakthrough technology for smaller aneurysms and that patients can do well with these treatments,” Dr. Hanel said. “This will make it widely available for use by more patients.”

The pipeline procedure is more efficient, Dr. Hanel added, compared to other techniques such as coiling because, once the aneurysm is closed off, the possibility of the aneurysm reoccurring with the pipeline is close to zero.

The Baptist Stroke & Cerebrovascular Center hopes to enroll 20 to 25 people during the next six months, ages 22 to 80, and will continue to enroll patients for two years. Patients will be followed for a five-year period.

“Baptist Jacksonville is at the forefront in the assessment of newer technologies to improve the care of patients with brain aneurysms and strokes,” said neurovascular surgeon Eric Sauvageau, MD, who directs the Stroke & Cerebrovascular Center with Dr. Hanel.

For Bean, who is married and a sales manager for a dairy, she said, “There is a huge weight lifted off.” She’ll be monitored during the coming months and in six months, the aneurysm is expected to be gone.

“It’s an amazing thing they are doing. I think of how many people this could save,” Bean said.

Every year, an estimated 40,000 people in the United States experience a ruptured cerebral aneurysm and about 4 percent of the population may be living with an unruptured aneurysm.

###

About Baptist Health

Baptist Health is a faith-based, mission-driven system in Northeast Florida comprised of Baptist Medical Center Jacksonville; Baptist Medical Center Beaches; Baptist Medical Center Nassau; Baptist Medical Center South; Baptist Clay Medical Campus and Wolfson Children’s Hospital – the region’s only children’s hospital. All Baptist Health hospitals, along with Baptist Home Health Care, have achieved Magnet™ status for excellence in patient care. Baptist Health includes the area’s only dedicated heart hospital; a cancer center; orthopedic institute; women’s services; neurological institute, including comprehensive neurosurgical services, a comprehensive stroke center and two primary stroke centers; a Bariatric Center of Excellence; a full range of psychology and psychiatry services; outpatient facilities; urgent care services; and primary and specialty care physicians’ offices throughout Northeast Florida. For more details, visit baptistjax.com. For information on Wolfson Children’s Hospital, visit http://www.wolfsonchildrens.org.







The Oliver Law Group P.C. is Investigating Cases of Melanoma In Men Who Took Sildenafil (Viagra) After Study Finds Potential Link


New York NY (PRWEB) September 11, 2014

The Oliver Law Group P.C. reports that a recently published study has found that the use of Sildenafil citrate, sold as Viagra and Revatio increases the risk for developing melanoma skin cancer. Research published in the June 2014 issue of JAMA Internal Medicine showed men who said they used sildenafil, the generic name for Viagra, had an 84 percent risk for having invasive melanoma compared to men who did not use Viagra and other sildenafil drugs. According to researchers, the study’s objective was to evaluate the link between sildenafil use and the melanoma risk among men in the United States. Researchers reviewed data from the Health Professional’s Follow-up Study in which 25,848 men were questioned in 2000 about whether they use sildenafil for erectile dysfunction. The average age of the participants were about 65 years old. Researchers said they identified 142 melanoma cases, 580 squamous cell carcinoma cases and 3,030 cases of basal cell carcinoma during a follow-up from 2000 to 2010. Researchers observed that participants who took Sildenafil (Viagra) were at almost twice the risk for developing the dangerous skin cancer melanoma. Researchers noted that they supported a need for continual investigation into the association of Viagra with melonoma skin cancer, but did not observe an increase in risks associated with Viagra and other sildenafil drug use and the different types of skin cancers. [archinte.jamanetwork.com/article.aspx?articleid=1857095, June 2014]

In a commentary that accompanied the article, Dr. June K. Robinson, of the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, and editor of JAMA Dermatology, wrote that a prospective study with clearly defined criteria and known doses of sildenafil taken is needed before recommending changes in how men use sildenafil. According to Dr. Robinson, about 76,100 new melanomas will be diagnosed in 2014, and an estimated 9,710 men and women will die as a result of the diagnosis. However, patients in the very early stage of the disease have a 5-year survival rate of 99 percent when the cancer is treated with excision, according to Dr. Robinson. Those who are in Stage IIB, when the tumor has spread further into the lower part of the skin, have a 5-year survival rate of 57 percent. Dr. Robinson wrote that early detection of melanoma is needed and surgical excision of the cancer is critical. [archinte.jamanetwork.com/article.aspx?articleid=1857089, June 2014]

Viagra was approved in 1998 by the U.S. Food & Drug Administration as a prescription medication to treat erectile dysfunction in men. The drug became known as the “blue pill” because of its distinct blue color. Pfizer Inc., the maker of Viagra, and other manufacturers of drugs that treat erectile dysfunctio such as Cialis and Levitra, were told by the FDA in July 2005 to update there labels to include sudden vision loss as a side-effect of taking the drug. Two years later, the FDA required the drug manufacturers to display more prominently the potential risk for sudden hearing loss and what consumers should do if they experience hearing problems. Since hearing loss is associated with the aging process, the FDA suggested that some men who use Viagra may not think to talk to their doctor about it. Currently, the Viagra labeling includes other risks of side-effects, such as headache, upset stomach, back pain, muscle pain, nausea and dizziness. Priapism, an erection that will not go away, has also been reported by men who have taken the drug. It is recommended that men seek medical attention immediately if they experience this serious side-effect.

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108458.htm, July 8, 2005]

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm, October 18, 2007]

If You Believe You Have Developed Melanoma or Skin Cancer Due To Use of Viagra or other Sildenafil Medications Contact The Oliver Group P.C. To Learn More About Your Legal Options

The Oliver Law Group P.C. is a different kind of national law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.

Experience. Dedication. Trust. Oliver Law Group P.C.

If you have developed melanoma skin cancer as a result of taking Sildenafil citrate, also known as Viagra, Revatio and under various other trade names,, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free Sildenafil melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit http://www.legalactionnow.com.







The Oliver Law Group P.C. is Investigating Cases of Melanoma In Men Who Took Sildenafil (Viagra) After Study Finds Potential Link


New York NY (PRWEB) September 11, 2014

The Oliver Law Group P.C. reports that a recently published study has found that the use of Sildenafil citrate, sold as Viagra and Revatio increases the risk for developing melanoma skin cancer. Research published in the June 2014 issue of JAMA Internal Medicine showed men who said they used sildenafil, the generic name for Viagra, had an 84 percent risk for having invasive melanoma compared to men who did not use Viagra and other sildenafil drugs. According to researchers, the study’s objective was to evaluate the link between sildenafil use and the melanoma risk among men in the United States. Researchers reviewed data from the Health Professional’s Follow-up Study in which 25,848 men were questioned in 2000 about whether they use sildenafil for erectile dysfunction. The average age of the participants were about 65 years old. Researchers said they identified 142 melanoma cases, 580 squamous cell carcinoma cases and 3,030 cases of basal cell carcinoma during a follow-up from 2000 to 2010. Researchers observed that participants who took Sildenafil (Viagra) were at almost twice the risk for developing the dangerous skin cancer melanoma. Researchers noted that they supported a need for continual investigation into the association of Viagra with melonoma skin cancer, but did not observe an increase in risks associated with Viagra and other sildenafil drug use and the different types of skin cancers. [archinte.jamanetwork.com/article.aspx?articleid=1857095, June 2014]

In a commentary that accompanied the article, Dr. June K. Robinson, of the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, and editor of JAMA Dermatology, wrote that a prospective study with clearly defined criteria and known doses of sildenafil taken is needed before recommending changes in how men use sildenafil. According to Dr. Robinson, about 76,100 new melanomas will be diagnosed in 2014, and an estimated 9,710 men and women will die as a result of the diagnosis. However, patients in the very early stage of the disease have a 5-year survival rate of 99 percent when the cancer is treated with excision, according to Dr. Robinson. Those who are in Stage IIB, when the tumor has spread further into the lower part of the skin, have a 5-year survival rate of 57 percent. Dr. Robinson wrote that early detection of melanoma is needed and surgical excision of the cancer is critical. [archinte.jamanetwork.com/article.aspx?articleid=1857089, June 2014]

Viagra was approved in 1998 by the U.S. Food & Drug Administration as a prescription medication to treat erectile dysfunction in men. The drug became known as the “blue pill” because of its distinct blue color. Pfizer Inc., the maker of Viagra, and other manufacturers of drugs that treat erectile dysfunctio such as Cialis and Levitra, were told by the FDA in July 2005 to update there labels to include sudden vision loss as a side-effect of taking the drug. Two years later, the FDA required the drug manufacturers to display more prominently the potential risk for sudden hearing loss and what consumers should do if they experience hearing problems. Since hearing loss is associated with the aging process, the FDA suggested that some men who use Viagra may not think to talk to their doctor about it. Currently, the Viagra labeling includes other risks of side-effects, such as headache, upset stomach, back pain, muscle pain, nausea and dizziness. Priapism, an erection that will not go away, has also been reported by men who have taken the drug. It is recommended that men seek medical attention immediately if they experience this serious side-effect.

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108458.htm, July 8, 2005]

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm, October 18, 2007]

If You Believe You Have Developed Melanoma or Skin Cancer Due To Use of Viagra or other Sildenafil Medications Contact The Oliver Group P.C. To Learn More About Your Legal Options

The Oliver Law Group P.C. is a different kind of national law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.

Experience. Dedication. Trust. Oliver Law Group P.C.

If you have developed melanoma skin cancer as a result of taking Sildenafil citrate, also known as Viagra, Revatio and under various other trade names,, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free Sildenafil melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit http://www.legalactionnow.com.







The Oliver Law Group P.C. is Investigating Cases of Melanoma In Men Who Took Sildenafil (Viagra) After Study Finds Potential Link


New York NY (PRWEB) September 11, 2014

The Oliver Law Group P.C. reports that a recently published study has found that the use of Sildenafil citrate, sold as Viagra and Revatio increases the risk for developing melanoma skin cancer. Research published in the June 2014 issue of JAMA Internal Medicine showed men who said they used sildenafil, the generic name for Viagra, had an 84 percent risk for having invasive melanoma compared to men who did not use Viagra and other sildenafil drugs. According to researchers, the study’s objective was to evaluate the link between sildenafil use and the melanoma risk among men in the United States. Researchers reviewed data from the Health Professional’s Follow-up Study in which 25,848 men were questioned in 2000 about whether they use sildenafil for erectile dysfunction. The average age of the participants were about 65 years old. Researchers said they identified 142 melanoma cases, 580 squamous cell carcinoma cases and 3,030 cases of basal cell carcinoma during a follow-up from 2000 to 2010. Researchers observed that participants who took Sildenafil (Viagra) were at almost twice the risk for developing the dangerous skin cancer melanoma. Researchers noted that they supported a need for continual investigation into the association of Viagra with melonoma skin cancer, but did not observe an increase in risks associated with Viagra and other sildenafil drug use and the different types of skin cancers. [archinte.jamanetwork.com/article.aspx?articleid=1857095, June 2014]

In a commentary that accompanied the article, Dr. June K. Robinson, of the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, and editor of JAMA Dermatology, wrote that a prospective study with clearly defined criteria and known doses of sildenafil taken is needed before recommending changes in how men use sildenafil. According to Dr. Robinson, about 76,100 new melanomas will be diagnosed in 2014, and an estimated 9,710 men and women will die as a result of the diagnosis. However, patients in the very early stage of the disease have a 5-year survival rate of 99 percent when the cancer is treated with excision, according to Dr. Robinson. Those who are in Stage IIB, when the tumor has spread further into the lower part of the skin, have a 5-year survival rate of 57 percent. Dr. Robinson wrote that early detection of melanoma is needed and surgical excision of the cancer is critical. [archinte.jamanetwork.com/article.aspx?articleid=1857089, June 2014]

Viagra was approved in 1998 by the U.S. Food & Drug Administration as a prescription medication to treat erectile dysfunction in men. The drug became known as the “blue pill” because of its distinct blue color. Pfizer Inc., the maker of Viagra, and other manufacturers of drugs that treat erectile dysfunctio such as Cialis and Levitra, were told by the FDA in July 2005 to update there labels to include sudden vision loss as a side-effect of taking the drug. Two years later, the FDA required the drug manufacturers to display more prominently the potential risk for sudden hearing loss and what consumers should do if they experience hearing problems. Since hearing loss is associated with the aging process, the FDA suggested that some men who use Viagra may not think to talk to their doctor about it. Currently, the Viagra labeling includes other risks of side-effects, such as headache, upset stomach, back pain, muscle pain, nausea and dizziness. Priapism, an erection that will not go away, has also been reported by men who have taken the drug. It is recommended that men seek medical attention immediately if they experience this serious side-effect.

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108458.htm, July 8, 2005]

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm, October 18, 2007]

If You Believe You Have Developed Melanoma or Skin Cancer Due To Use of Viagra or other Sildenafil Medications Contact The Oliver Group P.C. To Learn More About Your Legal Options

The Oliver Law Group P.C. is a different kind of national law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.

Experience. Dedication. Trust. Oliver Law Group P.C.

If you have developed melanoma skin cancer as a result of taking Sildenafil citrate, also known as Viagra, Revatio and under various other trade names,, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free Sildenafil melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit http://www.legalactionnow.com.







The Oliver Law Group P.C. is Investigating Cases of Melanoma In Men Who Took Sildenafil (Viagra) After Study Finds Potential Link


New York NY (PRWEB) September 11, 2014

The Oliver Law Group P.C. reports that a recently published study has found that the use of Sildenafil citrate, sold as Viagra and Revatio increases the risk for developing melanoma skin cancer. Research published in the June 2014 issue of JAMA Internal Medicine showed men who said they used sildenafil, the generic name for Viagra, had an 84 percent risk for having invasive melanoma compared to men who did not use Viagra and other sildenafil drugs. According to researchers, the study’s objective was to evaluate the link between sildenafil use and the melanoma risk among men in the United States. Researchers reviewed data from the Health Professional’s Follow-up Study in which 25,848 men were questioned in 2000 about whether they use sildenafil for erectile dysfunction. The average age of the participants were about 65 years old. Researchers said they identified 142 melanoma cases, 580 squamous cell carcinoma cases and 3,030 cases of basal cell carcinoma during a follow-up from 2000 to 2010. Researchers observed that participants who took Sildenafil (Viagra) were at almost twice the risk for developing the dangerous skin cancer melanoma. Researchers noted that they supported a need for continual investigation into the association of Viagra with melonoma skin cancer, but did not observe an increase in risks associated with Viagra and other sildenafil drug use and the different types of skin cancers. [archinte.jamanetwork.com/article.aspx?articleid=1857095, June 2014]

In a commentary that accompanied the article, Dr. June K. Robinson, of the Department of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, and editor of JAMA Dermatology, wrote that a prospective study with clearly defined criteria and known doses of sildenafil taken is needed before recommending changes in how men use sildenafil. According to Dr. Robinson, about 76,100 new melanomas will be diagnosed in 2014, and an estimated 9,710 men and women will die as a result of the diagnosis. However, patients in the very early stage of the disease have a 5-year survival rate of 99 percent when the cancer is treated with excision, according to Dr. Robinson. Those who are in Stage IIB, when the tumor has spread further into the lower part of the skin, have a 5-year survival rate of 57 percent. Dr. Robinson wrote that early detection of melanoma is needed and surgical excision of the cancer is critical. [archinte.jamanetwork.com/article.aspx?articleid=1857089, June 2014]

Viagra was approved in 1998 by the U.S. Food & Drug Administration as a prescription medication to treat erectile dysfunction in men. The drug became known as the “blue pill” because of its distinct blue color. Pfizer Inc., the maker of Viagra, and other manufacturers of drugs that treat erectile dysfunctio such as Cialis and Levitra, were told by the FDA in July 2005 to update there labels to include sudden vision loss as a side-effect of taking the drug. Two years later, the FDA required the drug manufacturers to display more prominently the potential risk for sudden hearing loss and what consumers should do if they experience hearing problems. Since hearing loss is associated with the aging process, the FDA suggested that some men who use Viagra may not think to talk to their doctor about it. Currently, the Viagra labeling includes other risks of side-effects, such as headache, upset stomach, back pain, muscle pain, nausea and dizziness. Priapism, an erection that will not go away, has also been reported by men who have taken the drug. It is recommended that men seek medical attention immediately if they experience this serious side-effect.

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108458.htm, July 8, 2005]

[fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109012.htm, October 18, 2007]

If You Believe You Have Developed Melanoma or Skin Cancer Due To Use of Viagra or other Sildenafil Medications Contact The Oliver Group P.C. To Learn More About Your Legal Options

The Oliver Law Group P.C. is a different kind of national law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.

Experience. Dedication. Trust. Oliver Law Group P.C.

If you have developed melanoma skin cancer as a result of taking Sildenafil citrate, also known as Viagra, Revatio and under various other trade names,, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact the Oliver Law Group P.C. for your free Sildenafil melanoma skin cancer lawsuit case review by calling 1-800-939-7878 today or visit http://www.legalactionnow.com.







With Humility Comes Achievement New PsychTests Study Indicates That Goal-achievers Are More Amenable to Coaching


Montreal, Canada (PRWEB) September 13, 2014

There have been several memorable “thank you” speeches from athletes, actors, and other award-winners. Adrien Brody’s smooch with Halle Berry after winning the Oscar for “Best Actor;” Roberto Beningni’s chair-leaping; Michael Sam’s speech that brought many to tears; and Nelson Mandela’s powerfully moving oration after winning the Nobel Peace Prize Award are just a few examples.

There is one common thread in all of these speeches, however: A sense of heartfelt gratitude to the people who helped these winners accomplish the amazing things they did. In fact, research from PsychTests indicates that it is their humbleness and willingness to accept advice, guidance, and even criticism from others that has made them a success.

After collecting data from 564 people who took the Coachability Test, researchers at PsychTests focused on two groups: Goal-achievers (those who have achieved most of the goals they have set for themselves) and Non-achievers (those who are floating through life without setting or achieving any major goals).

According to their statistics:

Goal-achievers are more open to coaching (score of 78 vs. 64 for Non-achievers, on a scale from 0 to 100).
Goal-achievers are more willing to accept criticism (score of 76 vs. 63 for Non-achievers).
Goal-achievers are more open to self-improvement (score of 88 vs. 71 for Non-achievers).
Goal-achievers are more comfortable admitting to their mistakes, failures, or weaknesses (score of 73 vs. 58 for Non-achievers).
Goal-achievers are more driven and perseverant (score of 91 vs. 57 for Non-achievers).
When goal-achievers need help, guidance, or advice, they are willing to turn to others (score of 73 vs. 61 for Non-achievers).

PsychTests research also indicates that among the Goal-achievers:

89% actively seek out opportunities to learn new things (compared to 31% of Non-achievers).
96% continuously look for ways to become a better person (compared to 50% of Non-achievers).
When they fail, 90% of goal-achievers will simply keep trying until they do succeed (compared to 25% of Non-achievers).
28% find it hard to admit to others when they can’t do something on their own (compared to 50% of Non-achievers).
When given advice for improvement by teachers, coaches, or managers, 82% will put the guidance they receive to good use. Only 44% of Non-achievers will listen to the counsel.

“Whether a person is an athlete or a high-powered executive, there’s a good chance that somewhere along their path to greatness, they received help or guidance from someone,” explains Dr. Jerabek, president of PsychTests.

“Non-achievers generally run into two issues: They either don’t believe they have what it takes to achieve the goals they aspire to, or they expect to be able to do everything on their own – as though asking others for help will diminish the value of their success. So they create more struggle and obstacles for themselves than is necessary. In order to benefit from coaching, you need to be willing to put your ego aside and accept guidance and criticism, as painful as it may be. And if you want to achieve your goals, you need to be able to admit when you can’t do something on your own and need help. That’s what humility is: Having the strength and courage to admit to your faults and shortcomings.”

Want to assess your level of coachability? Go to http://testyourself.psychtests.com/testid/3633

Professional users of this assessment (therapists, life coaches and counselors) can request a free demo of this or any other tests from ARCH Profile’s extensive battery: http://hrtests.archprofile.com/testdrive_gen_1

To learn more about psychological testing, download this free eBook: http://hrtests.archprofile.com/personality-tests-in-hr

About PsychTests.com

PsychTests.com is a subsidiary of PsychTests AIM Inc. PsychTests.com is a site that creates an interactive venue for self-exploration with a healthy dose of fun. The site offers a full range of professional-quality, scientifically validated psychological assessments that empower people to grow and reach their real potential through insightful feedback and detailed, custom-tailored analysis.

PsychTests AIM Inc. originally appeared on the internet scene in 1996. Since its inception, it has become a pre-eminent provider of psychological assessment products and services to human resource personnel, therapists, academics, researchers and a host of other professionals around the world. PsychTests AIM Inc. staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com). The company’s research division, Plumeus Inc., is supported in part by Research and Development Tax Credit awarded by Industry Canada.







With Humility Comes Achievement New PsychTests Study Indicates That Goal-achievers Are More Amenable to Coaching


Montreal, Canada (PRWEB) September 13, 2014

There have been several memorable “thank you” speeches from athletes, actors, and other award-winners. Adrien Brody’s smooch with Halle Berry after winning the Oscar for “Best Actor;” Roberto Beningni’s chair-leaping; Michael Sam’s speech that brought many to tears; and Nelson Mandela’s powerfully moving oration after winning the Nobel Peace Prize Award are just a few examples.

There is one common thread in all of these speeches, however: A sense of heartfelt gratitude to the people who helped these winners accomplish the amazing things they did. In fact, research from PsychTests indicates that it is their humbleness and willingness to accept advice, guidance, and even criticism from others that has made them a success.

After collecting data from 564 people who took the Coachability Test, researchers at PsychTests focused on two groups: Goal-achievers (those who have achieved most of the goals they have set for themselves) and Non-achievers (those who are floating through life without setting or achieving any major goals).

According to their statistics:

Goal-achievers are more open to coaching (score of 78 vs. 64 for Non-achievers, on a scale from 0 to 100).
Goal-achievers are more willing to accept criticism (score of 76 vs. 63 for Non-achievers).
Goal-achievers are more open to self-improvement (score of 88 vs. 71 for Non-achievers).
Goal-achievers are more comfortable admitting to their mistakes, failures, or weaknesses (score of 73 vs. 58 for Non-achievers).
Goal-achievers are more driven and perseverant (score of 91 vs. 57 for Non-achievers).
When goal-achievers need help, guidance, or advice, they are willing to turn to others (score of 73 vs. 61 for Non-achievers).

PsychTests research also indicates that among the Goal-achievers:

89% actively seek out opportunities to learn new things (compared to 31% of Non-achievers).
96% continuously look for ways to become a better person (compared to 50% of Non-achievers).
When they fail, 90% of goal-achievers will simply keep trying until they do succeed (compared to 25% of Non-achievers).
28% find it hard to admit to others when they can’t do something on their own (compared to 50% of Non-achievers).
When given advice for improvement by teachers, coaches, or managers, 82% will put the guidance they receive to good use. Only 44% of Non-achievers will listen to the counsel.

“Whether a person is an athlete or a high-powered executive, there’s a good chance that somewhere along their path to greatness, they received help or guidance from someone,” explains Dr. Jerabek, president of PsychTests.

“Non-achievers generally run into two issues: They either don’t believe they have what it takes to achieve the goals they aspire to, or they expect to be able to do everything on their own – as though asking others for help will diminish the value of their success. So they create more struggle and obstacles for themselves than is necessary. In order to benefit from coaching, you need to be willing to put your ego aside and accept guidance and criticism, as painful as it may be. And if you want to achieve your goals, you need to be able to admit when you can’t do something on your own and need help. That’s what humility is: Having the strength and courage to admit to your faults and shortcomings.”

Want to assess your level of coachability? Go to http://testyourself.psychtests.com/testid/3633

Professional users of this assessment (therapists, life coaches and counselors) can request a free demo of this or any other tests from ARCH Profile’s extensive battery: http://hrtests.archprofile.com/testdrive_gen_1

To learn more about psychological testing, download this free eBook: http://hrtests.archprofile.com/personality-tests-in-hr

About PsychTests.com

PsychTests.com is a subsidiary of PsychTests AIM Inc. PsychTests.com is a site that creates an interactive venue for self-exploration with a healthy dose of fun. The site offers a full range of professional-quality, scientifically validated psychological assessments that empower people to grow and reach their real potential through insightful feedback and detailed, custom-tailored analysis.

PsychTests AIM Inc. originally appeared on the internet scene in 1996. Since its inception, it has become a pre-eminent provider of psychological assessment products and services to human resource personnel, therapists, academics, researchers and a host of other professionals around the world. PsychTests AIM Inc. staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com). The company’s research division, Plumeus Inc., is supported in part by Research and Development Tax Credit awarded by Industry Canada.







With Humility Comes Achievement New PsychTests Study Indicates That Goal-achievers Are More Amenable to Coaching


Montreal, Canada (PRWEB) September 13, 2014

There have been several memorable “thank you” speeches from athletes, actors, and other award-winners. Adrien Brody’s smooch with Halle Berry after winning the Oscar for “Best Actor;” Roberto Beningni’s chair-leaping; Michael Sam’s speech that brought many to tears; and Nelson Mandela’s powerfully moving oration after winning the Nobel Peace Prize Award are just a few examples.

There is one common thread in all of these speeches, however: A sense of heartfelt gratitude to the people who helped these winners accomplish the amazing things they did. In fact, research from PsychTests indicates that it is their humbleness and willingness to accept advice, guidance, and even criticism from others that has made them a success.

After collecting data from 564 people who took the Coachability Test, researchers at PsychTests focused on two groups: Goal-achievers (those who have achieved most of the goals they have set for themselves) and Non-achievers (those who are floating through life without setting or achieving any major goals).

According to their statistics:

Goal-achievers are more open to coaching (score of 78 vs. 64 for Non-achievers, on a scale from 0 to 100).
Goal-achievers are more willing to accept criticism (score of 76 vs. 63 for Non-achievers).
Goal-achievers are more open to self-improvement (score of 88 vs. 71 for Non-achievers).
Goal-achievers are more comfortable admitting to their mistakes, failures, or weaknesses (score of 73 vs. 58 for Non-achievers).
Goal-achievers are more driven and perseverant (score of 91 vs. 57 for Non-achievers).
When goal-achievers need help, guidance, or advice, they are willing to turn to others (score of 73 vs. 61 for Non-achievers).

PsychTests research also indicates that among the Goal-achievers:

89% actively seek out opportunities to learn new things (compared to 31% of Non-achievers).
96% continuously look for ways to become a better person (compared to 50% of Non-achievers).
When they fail, 90% of goal-achievers will simply keep trying until they do succeed (compared to 25% of Non-achievers).
28% find it hard to admit to others when they can’t do something on their own (compared to 50% of Non-achievers).
When given advice for improvement by teachers, coaches, or managers, 82% will put the guidance they receive to good use. Only 44% of Non-achievers will listen to the counsel.

“Whether a person is an athlete or a high-powered executive, there’s a good chance that somewhere along their path to greatness, they received help or guidance from someone,” explains Dr. Jerabek, president of PsychTests.

“Non-achievers generally run into two issues: They either don’t believe they have what it takes to achieve the goals they aspire to, or they expect to be able to do everything on their own – as though asking others for help will diminish the value of their success. So they create more struggle and obstacles for themselves than is necessary. In order to benefit from coaching, you need to be willing to put your ego aside and accept guidance and criticism, as painful as it may be. And if you want to achieve your goals, you need to be able to admit when you can’t do something on your own and need help. That’s what humility is: Having the strength and courage to admit to your faults and shortcomings.”

Want to assess your level of coachability? Go to http://testyourself.psychtests.com/testid/3633

Professional users of this assessment (therapists, life coaches and counselors) can request a free demo of this or any other tests from ARCH Profile’s extensive battery: http://hrtests.archprofile.com/testdrive_gen_1

To learn more about psychological testing, download this free eBook: http://hrtests.archprofile.com/personality-tests-in-hr

About PsychTests.com

PsychTests.com is a subsidiary of PsychTests AIM Inc. PsychTests.com is a site that creates an interactive venue for self-exploration with a healthy dose of fun. The site offers a full range of professional-quality, scientifically validated psychological assessments that empower people to grow and reach their real potential through insightful feedback and detailed, custom-tailored analysis.

PsychTests AIM Inc. originally appeared on the internet scene in 1996. Since its inception, it has become a pre-eminent provider of psychological assessment products and services to human resource personnel, therapists, academics, researchers and a host of other professionals around the world. PsychTests AIM Inc. staff is comprised of a dedicated team of psychologists, test developers, researchers, statisticians, writers, and artificial intelligence experts (see ARCHProfile.com). The company’s research division, Plumeus Inc., is supported in part by Research and Development Tax Credit awarded by Industry Canada.